Drug Repositioning in Glioblastoma: A Pathway Perspective
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is the most malignant primary adult brain tumor. The current standard of care is surgical resection, radiation, and chemotherapy treatment, which extends life in most cases. Unfortunately, tumor recurrence is nearly universal and patients with recurrent glioblastoma typically survive <1 year. Therefore, new therapies and therapeutic combinations need to be developed that can be quickly approved for use in patients. However, in order to gain approval, therapies need to be safe as well as effective. One possible means of attaining rapid approval is repurposing FDA approved compounds for GBM therapy. However, candidate compounds must be able to penetrate the blood-brain barrier (BBB) and therefore a selection process has to be implemented to identify such compounds that can eliminate GBM tumor expansion. We review here psychiatric and non-psychiatric compounds that may be effective in GBM, as well as potential drugs targeting cell death pathways. We also discuss the potential of data-driven computational approaches to identify compounds that induce cell death in GBM cells, enabled by large reference databases such as the Library of Integrated Network Cell Signatures (LINCS). Finally, we argue that identifying pathways dysregulated in GBM in a patient specific manner is essential for effective repurposing in GBM and other gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 2×
“Collectively, these findings necessitate the discovery of novel therapeutic avenues for treating GBM. Impressive technological advances have enabled us to decipher the genetic and cellular makeup of GBM tumors (Verhaak et al., 2010; Clarke et al., 2013).”
BackgroundLamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 2×
“…of GBM. Advances in single cell sequencing allow the characterization of sub-populations in individual GBM tumors based on gene expression to identify small molecules that have the greatest probability of affecting pathways common in all malignant cells within a tumor (Patel et al., 2014).”
BackgroundDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836 · cited 1×
“Escape from apoptosis is also one of the hallmarks of carcinogenesis, including the progression of GBM (Wong, 2011).”
BackgroundJung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 1×
“…public resources such as ChEMBL (Bento et al., 2014) and PubChem (Wang et al., 2017a) or licensed databases such as the KKB (Sharma et al., 2016) in combination with machine learning (Nidhi et al., 2006; Schurer andMuskal, 2013; Bento et al., 2014) or statistical scoring (Keiser et al., 2009).”
BackgroundItakura, E., & Mizushima, N. (2010) · Autophagy · doi:10.4161/auto.6.6.12709 · Cited by 843 · cited 1×
“Jane et al. demonstrated that dinaciclib, which selectively inhibits CDK1, CDK2, CDK5, and CDK9, can reduce GBM cell proliferation independent of p53 status (Jane et al., 2016).”
BackgroundAlcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature · doi:10.1038/nature25016 · Cited by 807 · cited 1×
“The chelation product after disulfiram ingestion, the DTC-copper complex, was hypothesized to bind NPL4, and subsequently inhibit the p97 pathway, thus resulting in cell death (Skrott et al., 2017) (Figure 1).”
BackgroundDeep Learning in Drug Discovery
Gawehn, E., Hiss, J. A., & Schneider, G. (2016) · Molecular Informatics · doi:10.1002/minf.201501008 · Cited by 723 · cited 1×
“As in many other areas deep learning has recently received a lot of attention (Gawehn et al., 2016).”
BackgroundNecroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features
Berghe, T. V., Vanlangenakker, N., Parthoens, E., Deckers, W., Devos, M., Festjens, N., Guerin, C. J., Brunk, U. T., Declercq, W., & Vandenabeele, P. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.184 · Cited by 639
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Keenan, A. B., Jenkins, S. L., Jagodnik, K. M., Koplev, S., He, E., Torre, D., Wang, Z., Dohlman, A. B., Silverstein, M. C., Lachmann, A., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2017.11.001 · Cited by 423 · cited 1×
“These data have been generated as part of the Library of Integrated Network-based Cellular Signatures (LINCS) project along with several other cellular perturbation response signatures and computational tools (Keenan et al., 2017).”
MethodSelf-citationRegulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis
Geng, J., Ito, Y., Shi, L., Amin, P., Chu, J., Ouchida, A. T., Mookhtiar, A. K., Zhao, H., Xu, D., Shan, B., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00406-w · Cited by 325
Self-citationDrugCentral: online drug compendium
Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J., & Oprea, T. I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw993 · Cited by 323 · cited 1×
“Importantly, several well annotated databases of approved drugs and compounds in clinical trials are publicly available including ChEMBL (Bento et al., 2014), DrugBank (Wishart et al., 2006), and DrugCentral (Ursu et al., 2017).”
BackgroundPharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279 · cited 1×
“All IDG data and a query interface are available via the Pharos Data Portal (Nguyen et al., 2017).”
MethodSelf-citationOn the Integration of In Silico Drug Design Methods for Drug Repurposing
March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., & Rastelli, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00298 · Cited by 235 · cited 1×
“Cheminformatics ligand- and structurebased repositioning approaches are well established and have also been extensively reviewed for drug repositioning, for example recently by March-Vila et al. (2017).”
BackgroundAntiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor077 · Cited by 201 · cited 1×
“Furthermore, mebendazole polymorph C shows a survival benefit in a model of C57BL/6 mice bearing GL261 cells (Bai et al., 2011, 2015; DeWitt et al., 2017).”
BackgroundLun, X., Wells, J. C., Grinshtein, N., King, J. C., Hao, X., Dang, N.-H., Wang, X., Aman, A., Uehling, D., Datti, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1798 · Cited by 197 · cited 1×
“Disulfiram is pharmacokinetically converted into a smaller metabolite called diethyldithiocarbamate (DTC), which chelates with copper or zinc ions (Chen et al., 2006; Lun et al., 2016).”
BackgroundKoleti, A., Terryn, R., Stathias, V., Chung, C., Cooper, D. J., Turner, J. P., Vidović, D., Forlin, M., Kelley, T. T., D’Urso, A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1063 · Cited by 193
Self-citationCancer mortality in patients with schizophrenia: An 11‐year prospective cohort study
Tran, E., Rouillon, F., Loze, J., Casadebaig, F., Philippe, A., Vitry, F., & Limosin, F. (2009) · Cancer · doi:10.1002/cncr.24383 · Cited by 173 · cited 1×
“Interestingly, the incidence of cancer occurrence is inversely proportional to antipsychotic drug treatment in patients with schizophrenia, perhaps suggesting that there is a benefit to treatment with antipsychotic drugs for cancer patients (Barak et al., 2005; Tran et al., 2009).”
BackgroundReduced cancer incidence among patients with schizophrenia
Barak, Y., Achiron, A., Mandel, M., Mirecki, I., & Aizenberg, D. (2005) · Cancer · doi:10.1002/cncr.21574 · Cited by 159 · cited 1×
“Interestingly, the incidence of cancer occurrence is inversely proportional to antipsychotic drug treatment in patients with schizophrenia, perhaps suggesting that there is a benefit to treatment with antipsychotic drugs for cancer patients (Barak et al., 2005; Tran et al., 2009).”
BackgroundRepurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors
De Witt, M., Gamble, A., Hanson, D., Markowitz, D., Powell, C., Al Dimassi, S., Atlas, M., Boockvar, J., Ruggieri, R., & Symons, M. (2017) · Molecular Medicine · doi:10.2119/molmed.2017.00011 · Cited by 86 · cited 6×
“It was demonstrated by De Witt et al. that mebendazole inhibits microtubule polymerization and induces metaphase arrest, very similar to the mechanism of action of another microtubule inhibitor, vincristine (De Witt et al., 2017) (Figure 1).”
BackgroundInfluentialTranslational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77 · cited 1×
“Following DNA damage, p53 is activated and induces the transcription of response genes such as p21Cip1, a negative regulator of the cell cycle, or BCL-2-like protein 4 (BAX), a mediator of apoptosis (Essmann and Schulze-Osthoff, 2012).”
Background
Cited by
Are the Statins promising antifungal agents against invasive candidiasis?
Lima, W. G., Alves-Nascimento, L. A., Andrade, J. T., Vieira, L., de Azambuja Ribeiro, R. I. M., Thomé, R. G., dos Santos, H. B., Ferreira, J. M. S., & Soares, A. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.076 · Cited by 65
Omoruyi, S. I., Ekpo, O. E., Semenya, D. M., Jardine, A., & Prince, S. (2020) · Apoptosis · doi:10.1007/s10495-020-01594-5 · Cited by 53
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
Metadata
- Authors
- Tan, S. K., Jermakowicz, A., Mookhtiar, A. K., Nemeroff, C. B., Schürer, S. C., & Ayad, N. G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-16
- Volume
- 9
- Pages
- 218-218
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2793742848
- Cited by
- 116
- References
- 26
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.